Stereo-Specific Modulation of the Extracellular Calcium-Sensing Receptor in Colon Cancer Cells.

Area of Science:

• Pharmacology
• Oncology
• Molecular Biology

Background:

• Pharmacological calcimimetics (CaSR agonists) cause gastrointestinal issues and inflammation in colon cancer.
• The precise mechanism requires differentiating CaSR-mediated effects from off-target drug actions.

Purpose of the Study:

• To determine if CaSR activation or off-target effects mediate inflammation in colon cancer cells.
• To validate the role of CaSR in drug-induced inflammatory responses.

Main Methods:

• Comparison of CaSR-specific (R) and non-specific (S) enantiomers of calcimimetic (NPS 568) and calcilytic (NPS 2143) drugs.
• Assessment of CaSR and interleukin-8 (IL-8) expression in HT29 colon cancer cells using RT-qPCR and ELISA.
• Characterization of NPS S-2143 in HEK-CaSR cells to confirm lack of CaSR inhibition.

Main Results:

• Only CaSR-selective enantiomers of NPS 568 and NPS 2143 modulated CaSR and IL-8 expression.
• The non-CaSR selective enantiomer NPS S-2143 did not inhibit CaSR-mediated signals in HEK-CaSR cells.
• Inflammatory effects in colon cancer cells were confirmed to be CaSR-mediated.

Conclusions:

• CaSR activation, not off-target effects, is responsible for pro-inflammatory responses in colon cancer cells.
• CaSR-selective drugs are crucial for targeted therapeutic strategies.
• NPS S-2143 serves as a valuable tool for studying CaSR-mediated processes.